Abstract
Jasmonates are plant stress hormones that induce suppression of proliferation and death in cancer cells, while being selectively inactive towards non-transformed cells. Jasmonates can overcome apoptotic blocks and exert cytotoxic effects on drug-resistant cells expressing p53 mutations. Jasmonates induce a rapid depletion of ATP in cancer cells. Indeed, this steep drop occurs when no signs of cell death are detectable yet. Experiments using modulators of ATP synthesis via glycolysis or oxidative phosphorylation suggest that the latter is the pathway suppressed by jasmonates. Consequently, the direct effects of jasmonates on mitochondria were evaluated. Jasmonates induced cytochrome c release and swelling in mitochondria isolated from cancer cells but not from normal ones. Thus, the selectivity of jasmonates against cancer cells is rooted at the mitochondrial level, and probably exploits differences between mitochondria from normal versus cancer cells. These findings position jasmonates as promising anti-cancer drugs acting via energetic depletion in neoplastic cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aito H, Aalto KT, Raivio KO (2002) Pediatr Res 52:40–45
Amin R, Kamitani H, Sultana H, Taniura S, Islam A, Sho A, Ishibashi M, Eling TE, Watanabe T (2003) Neurol Res 25:370–376
Ara G, Teicher BA (1996) Prostaglandins Leukot Essent Fatty Acids 54:3–16
Arathi G, Sachdanandam P (2003) J Pharm Pharmacol 55:1283–1290
Bellosillo B, Pique M, Barragan M, Castano E, Villamor N, Colomer D, Montserrat E, Pons G, Gil J (1998) Blood 92:1406–1414
Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA (2006) J Biol Chem Published online ahead of print
Brenner C, Grimm S (2006) Oncogene 25:4744–4756
Chen LB (1988) Ann Rev Cell Biol 4:155–181
Chung YM, Bae YS, Lee SY (2003) Free Radic Biol Med 34:434–442
Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC (2002) Cancer Res 62:6674–6681
Dang CV, Semenza GL (1999) Trends Biochem Sci 24:68–72
Debatin K-M, Poncet D, Kroemer G (2002) Oncogene 21:8786–8803
Elder DJ, Hague A, Hicks DJ, Paraskeva C (1996) Cancer Res 56:2273–2276
Fingrut O, Flescher E (2002) Leukemia 16:608–616
Fingrut O, Reischer D, Rotem R, Goldin N, Altboum I, Zan-Bar I, Flescher E (2005) Br J Pharmacol 146:800–808
Flescher E (2005) Anticancer Drugs 16:911–916
Flescher, E. (2007). Cancer Lett. 245:1–10
Frydman B, Bhattacharya S, Sarkar A, Drandarov K, Chesnov S, Guggisberg A, Popaj K, Sergeyev S, Yurdakul A, Hesse M, Basu HS, Marton LJ (2004) J Med Chem 47:1051–1059
Fulton AM (1987) J Natl Cancer Inst 78:735–741
Gaikwad A, Poblenz A, Haridas V, Zhang C, Duvic M, Gutterman J (2005) Clin Cancer Res 11:1953–1962
Galuzzi L, Larochette N, Zamzami N, Kroemer G (2006) Oncogene 25:4812–4830
Gerhäuser C, Lee SK, Kosmeder JW, Moriarty RM, Hamel E, Mehta RG, Moon EC, Pezzuto JM (1997) Cancer Res 57:3429–3435
Ghezzo F, Cesano L, Mognetti B, Pesce E, Pirro E, Corvetti G, Berta GN, Zingaro B, Di Carlo F (2005) Int J Oncol 26:697–702
Ha HC, Snyder SH (1999) PNAS (USA) 96:13978–13982
Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B (1996) Biochem Pharmacol 52:237–245
Healy DA, Watson RW, Newscholme P (2002) Clin Sci (Lond.) 103:179–189
Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaria G, Chamorro M, Reed JC, Cuezva JM (2004) Biochem J 378:17–20
Kim JH, Lee SY, Oh SY, Han SI, Park HG, Yoo MA, Kang HS (2004) Oncol Rep 12:1233–1238
Klampfer L, Cammenga J, Wisniewski HG, Nimer SD (1999) Blood 93:2386–2394
Komatsu N, Nakagawa M, Oda T, Muramatsu T (2000) J Biochem (Tokyo) 128:463–470
Kutty RK, Santostasi G, Horng J, Krishna G (1991) Toxicol Appl Pharmacol 107:377–388
Lee EJ, Park HG, Kang HS (2003) Int J Oncol 23:503–508
Levin M, Goldbarg S, Lindqvist A, Sward K, Roman C, Liu BM, Hulten LM, Boren J, Clyman RI (2005) Pediatr Res 57:801–805
Lyamzaev KG, Izyumov DS, Avetisyan VA, Yang F, Pletjushkina OY, Chernyak BV (2004) Acta Biochim Pol 51:553–562
Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ (2004) Cancer Res 64:31–34
Ordan O, Rotem R, Jaspers I, Flescher E (2003) Br J Pharmacol 138:1156–1162
Pedersen PL (1978) Prog Exp Tumor Res 22:190–274
Rotem R, Fingrut O, Moskovitz J, Flescher E (2003) Leukemia 17:2230–2234
Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, Flescher E (2005) Cancer Res 65:1984–1993
Rotem R, Tzivony Y, Flescher E (2000) Prostate 42:172–180
Salomon AR, Voehringer DW, Herzenberg LA, Khosla C (2000) PNAS 97:14766–14771
Samaila D, Ezekwudo DE, Yimam KK, Elegbede JA (2004) Trans Integrated Biomed Inform Enabling Tech Symp J 1:34–42 (Published online at www.tibetsjournal.org)
Saraswathi V, Ramamoorthy N, Subramaniam S, Mathuram V, Gunasekaran P, Govindasamy S (1998) Chemotherapy 44:198–205
Shiff SJ, Koutsos MI, Qiao L, Rigas B (1996) Exp Cell Res 222:179–188
Sivalokanathan S, Hayaraja M, Balasubramanian MP (2005) Indian J Exp Biol 43:264–267
Sotiriou C, Lacroix M, Lagneaux L, Berchem G, Body JJ (1999) Anticancer Res 19:2997–3006
Tiwari BS, Belenghi B, Levine A (2002) Plant Physiol 128:1271–1281
Warburg O, Dickens F, Kaiser Wilhelm-Institut für Biologie B (1930) The Metabolism of Tumours: Investigations from the Kaiser-Wilhelm Institute for Biology, Berlin-Dahlem. Constable: London
Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB (2004) Genes Dev 18:1272–1282
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goldin, N., Heyfets, A., Reischer, D. et al. Mitochondria-mediated ATP depletion by anti-cancer agents of the jasmonate family. J Bioenerg Biomembr 39, 51–57 (2007). https://doi.org/10.1007/s10863-006-9061-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-006-9061-y